Developing vaccines to protect against Ebola and related viruses
Official title: Advanced Development of Vaccines for Filoviruses
Funded at Auro Vaccines LLC · NIH-10382998 · Data updated 2026-11-12
This study is working on a new vaccine that could help protect people from several serious viruses like Ebola, Marburg, and Lassa Fever, and it’s designed to be easy to store and use, making it safer and more accessible for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auro Vaccines LLC NIH-funded |
| Lab location | 1 site (East Windsor, United States) |
| Project start | July 21, 2020 |
| Project end | December 31, 2026 |
| Funding year | 2021 |
| Award (this year) | $986,612 |
| NIH project number | 75N93020C00040-P00001-9999-1 |
| Project ID | NIH-10382998 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals at high risk of exposure to Ebola, Marburg, or Lassa Fever, such as healthcare workers or those living in endemic regions.
✕Less likely to help
Patients who are not at risk of exposure to these viruses or who have already been vaccinated against them may not benefit from this research.
What this research studies
This research focuses on creating a multivalent vaccine that can protect against several dangerous viruses, including Ebola, Marburg, and Lassa Fever. The approach involves formulating a stable vaccine that can be lyophilized, which means it can be dried and stored for easier distribution and use. The research will also support the manufacturing process under strict guidelines to ensure safety and effectiveness, and it aims to prepare the necessary documentation for clinical trials to evaluate the vaccine's performance in humans.
Why it matters
Potential benefit: If successful, this research could provide a new vaccine that protects against multiple deadly viruses, potentially saving many lives.
How similar studies have gone: Other research has shown promise in developing vaccines for similar viral infections, indicating that this approach could be effective.
Where this research is happening
-
Auro Vaccines LLC
East Windsor, United States Active
Researchers
- Principal investigator: Eldridge, John — Auro Vaccines LLC
- Study coordinator: Eldridge, John
Related research
Other NIH-funded projects on the same topics.
-
Developing vaccines to protect against Ebola and related viruses
This study is working on a new vaccine that could help protect people from several serious viruses like Ebola, Marburg, and Lassa Fever, making it easier to store and distribute, so it can be tested in the future to keep everyone safer.
-
Developing vaccines to protect against Ebola and Marburg viruses
This study is working on a new vaccine that aims to protect people from several serious viruses, like Ebola and Marburg, as well as Lassa Fever, making it easier to store and distribute, so that one day, patients can have better protection against these infections.
-
Developing vaccines to protect against Ebola and related viruses
This study is working on a new vaccine that aims to protect people from several serious viruses, like Ebola and Marburg, and it hopes to make it easier to store and distribute, so that one day, patients can have better protection against these infections.
-
Developing vaccines to protect against Ebola and related viruses
This study is working on a new vaccine that could help protect people from serious viruses like Ebola, Marburg, and Lassa Fever, making it easier to store and transport so it can be used to keep everyone safe in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.